Popularized in films like Limitless, legal smart drugs called Nootropics are becoming more and more prevalent in board rooms and on Wall Street.Keep reading »
Goldman Sachs Group Inc. said it had drawn scrutiny in regulatory inquiries related to high-frequency trading and whether its hiring practices complied with U.S. antibribery laws, according to a securities filing.
References to the investigations appeared in Friday’s quarterly filing with the Securities and Exchange Commission, in a list of reviews Goldman faces from government agencies and industry regulators. It marked the first time Goldman had disclosed each probe publicly. A spokesman for the bank declined to comment….
In Friday’s filing, Goldman also said it was a defendant in an April 18 class-action lawsuit related to high-speed trading. The action alleges that a number of exchanges and securities firms violated market-manipulation and insider-trading rules.